Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Chemotherapy, Adjuvant"" wg kryterium: Temat


Tytuł:
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective.
Autorzy:
Bradbury M; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Savard MF; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Vandermeer L; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Clemons L; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Pond G; Department of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.
Hilton J; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Clemons M; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
McGee S; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Dec 14; Vol. 30 (12), pp. 10477-10487. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/drug therapy
Chemotherapy, Adjuvant*/methods
Female ; Humans ; Canada ; Physicians ; Receptor, ErbB-2 ; Trastuzumab/therapeutic use
Czasopismo naukowe
Tytuł:
Tumor response to neoadjuvant chemotherapy in molecular breast cancer subtypes in Medellin, Colombia. Retrospective cohort study
Autorzy:
Restrepo-Mejía M; Corporación Universitaria Remington, Medellín (Colombia).. .
Guarín-García AM; Corporación Universitaria Remington, Medellín (Colombia).. .
Bonilla-Sepúlveda ÓA; Corporación Universitaria Remington, Medellín (Colombia).. .
Rincón-Medina M; Corporación Universitaria Remington, Medellín (Colombia).. .
Barrera-Arenas LM; Corporación Universitaria Remington, Medellín (Colombia).. .
Pokaż więcej
Transliterated Title:
Respuesta tumoral a la quimioterapia neoadyuvante en subtipos moleculares de cáncer de mama en Medellín, Colombia. Estudio de cohorte retrospectivo
Źródło:
Revista colombiana de obstetricia y ginecologia [Rev Colomb Obstet Ginecol] 2023 Jun 30; Vol. 74 (2), pp. 143-152. Date of Electronic Publication: 2023 Jun 30.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Chemotherapy, Adjuvant*
Neoadjuvant Therapy*
Adolescent ; Adult ; Female ; Humans ; Middle Aged ; Colombia/epidemiology ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study.
Autorzy:
Poiraud C; Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France.; University of Lille, 59000, Lille, France.
Lenne X; Department of Medical Information, CHRU de Lille, 59000, Lille, France.; University of Lille, 59000, Lille, France.
Bruandet A; Department of Medical Information, CHRU de Lille, 59000, Lille, France.; University of Lille, 59000, Lille, France.
Theis D; Department of Medical Information, CHRU de Lille, 59000, Lille, France.; University of Lille, 59000, Lille, France.
Bertrand N; Medical Oncology Department, CHU de Lille, 59000, Lille, France.; University of Lille, 59000, Lille, France.
Turpin A; Medical Oncology Department, CHU de Lille, 59000, Lille, France.; University of Lille, 59000, Lille, France.
Truant S; Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France.; University of Lille, 59000, Lille, France.
El Amrani M; Digestive Surgery and Transplantation Department, CHU de Lille, 59000, Lille, France. mehdi_.; University of Lille, 59000, Lille, France. mehdi_.; Service de Chirurgie Digestive Et Transplantation, Hôpital CLAUDE HURIEZ, Rue Michel Polonovski LILLE CEDEX, 59037, Lille, France. mehdi_.
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2024 May 06; Vol. 22 (1), pp. 123. Date of Electronic Publication: 2024 May 06.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/surgery
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Carcinoma, Pancreatic Ductal*/surgery
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/pathology
Pancreatectomy*/statistics & numerical data
Humans ; Female ; Male ; Aged ; Chemotherapy, Adjuvant/statistics & numerical data ; Chemotherapy, Adjuvant/methods ; France/epidemiology ; Middle Aged ; Aged, 80 and over ; Prognosis ; Follow-Up Studies ; Pancreaticoduodenectomy/statistics & numerical data ; Pancreaticoduodenectomy/methods ; Postoperative Complications/epidemiology ; Survival Rate ; Retrospective Studies ; Gemcitabine ; Risk Factors ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use
Czasopismo naukowe
Tytuł:
Eugenol as a potential adjuvant therapy for gingival squamous cell carcinoma.
Autorzy:
Issa H; GREB Research Group, Faculty of Dentistry, Laval University, Québec, Canada.
Loubaki L; Héma-Québec, Medical Affairs and Innovation, Québec, Canada.
Al Amri A; Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia.
Zibara K; PRASE and Biology Department, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon.
Almutairi MH; Zoology Department, College of Science, King Saud University, Riyadh, Saudi Arabia.
Rouabhia M; GREB Research Group, Faculty of Dentistry, Laval University, Québec, Canada.
Semlali A; GREB Research Group, Faculty of Dentistry, Laval University, Québec, Canada. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 May 13; Vol. 14 (1), pp. 10958. Date of Electronic Publication: 2024 May 13.
Typ publikacji:
Journal Article
MeSH Terms:
Eugenol*/pharmacology
Eugenol*/therapeutic use
Gingival Neoplasms*/drug therapy
Gingival Neoplasms*/pathology
Gingival Neoplasms*/metabolism
Carcinoma, Squamous Cell*/drug therapy
Carcinoma, Squamous Cell*/pathology
Carcinoma, Squamous Cell*/metabolism
Cell Proliferation*/drug effects
Apoptosis*/drug effects
Humans ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Cycle Checkpoints/drug effects ; Chemotherapy, Adjuvant/methods
Czasopismo naukowe
Tytuł:
A nomogram based on nutritional and inflammatory parameters to predict DMFS and identify beneficiaries of adjuvant chemotherapy in IVA-stage nasopharyngeal carcinoma.
Autorzy:
Pan Y; Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, 350014, China.
Chen Z; Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Hong W; Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Huang Z; Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Li Y; Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Cai S; Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, China.
Lai J; Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, 350014, China.
Lu J; Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, 350014, China.
Qiu S; Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center), Fuzhou, Fujian, 350014, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 May 11; Vol. 24 (1), pp. 578. Date of Electronic Publication: 2024 May 11.
Typ publikacji:
Journal Article
MeSH Terms:
Nomograms*
Nasopharyngeal Carcinoma*/drug therapy
Nasopharyngeal Carcinoma*/mortality
Nasopharyngeal Carcinoma*/pathology
Neoplasm Staging*
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/mortality
Nasopharyngeal Neoplasms*/pathology
Humans ; Male ; Female ; Middle Aged ; Chemotherapy, Adjuvant/methods ; Prognosis ; Inflammation ; Adult ; Nutrition Assessment ; Herpesvirus 4, Human/isolation & purification ; Tegafur/therapeutic use ; Tegafur/administration & dosage ; DNA, Viral ; Drug Combinations ; Oxonic Acid/therapeutic use ; Oxonic Acid/administration & dosage ; Aged ; Kaplan-Meier Estimate
Czasopismo naukowe
Tytuł:
The prognostic and predictive significance of perineural invasion in stage I to III colon cancer: a propensity score matching-based analysis.
Autorzy:
Chu CH; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
Lai IL; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
Jong BK; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
Chiang SF; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
Tsai WS; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
Hsieh PS; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
Yeh CY; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan.
You JF; Division of Colon and Rectal Surgery, Department of Surgery, College of Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2024 May 11; Vol. 22 (1), pp. 129. Date of Electronic Publication: 2024 May 11.
Typ publikacji:
Journal Article
MeSH Terms:
Propensity Score*
Neoplasm Invasiveness*
Colonic Neoplasms*/pathology
Colonic Neoplasms*/mortality
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/surgery
Neoplasm Staging*
Peripheral Nerves*/pathology
Humans ; Female ; Male ; Middle Aged ; Prognosis ; Aged ; Prospective Studies ; Survival Rate ; Chemotherapy, Adjuvant/methods ; Follow-Up Studies ; Lymphatic Metastasis ; Adult ; Taiwan/epidemiology
Czasopismo naukowe
Tytuł:
Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.
Autorzy:
He Q; Department of Oncology, the Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, Guizhou, 550004, P.R. China.; Department of Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, P.R. China.; School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, 550004, P.R. China.
Luo X; Department of Oncology, the Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, Guizhou, 550004, P.R. China.; Department of Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, P.R. China.
Liu L; Department of Oncology, the Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, Guizhou, 550004, P.R. China.; Department of Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, P.R. China.; School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, 550004, P.R. China.
Zhao C; Department of Oncology, the Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, Guizhou, 550004, P.R. China.; Department of Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, P.R. China.
Li Z; Department of Oncology, the Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, Guizhou, 550004, P.R. China.; Department of Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, P.R. China.; School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, 550004, P.R. China.
Jin F; Department of Oncology, the Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang, Guizhou, 550004, P.R. China. .; Department of Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, P.R. China. .; School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, 550004, P.R. China. .
Pokaż więcej
Źródło:
BMC immunology [BMC Immunol] 2024 May 06; Vol. 25 (1), pp. 28. Date of Electronic Publication: 2024 May 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Capecitabine*/administration & dosage
Capecitabine*/therapeutic use
Nasopharyngeal Carcinoma*/drug therapy
Nasopharyngeal Carcinoma*/immunology
Nasopharyngeal Carcinoma*/mortality
Administration, Metronomic*
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/immunology
Humans ; Male ; Female ; Middle Aged ; Adult ; Chemotherapy, Adjuvant/methods ; CD8-Positive T-Lymphocytes/immunology ; Aged ; Neoplasm Staging ; Treatment Outcome ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use ; Follow-Up Studies
Czasopismo naukowe
Tytuł:
An isolated vaginal metastasis from rectal cancer: a case report.
Autorzy:
Sakhri S; Department of Surgical Oncology, Faculty of Medicine of Tunis, Salah Azaiez Institute, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis, Tunisia. .
Zemni I; Department of Surgical Oncology, Faculty of Medicine of Tunis, Salah Azaiez Institute, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis, Tunisia.; LMBA (LR03ES03), Sciences Faculty of Tunis, University Tunis el Manar, Tunis, Tunisia.
Ayadi MA; Department of Surgical Oncology, Faculty of Medicine of Tunis, Salah Azaiez Institute, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis, Tunisia.; LMBA (LR03ES03), Sciences Faculty of Tunis, University Tunis el Manar, Tunis, Tunisia.
Ghazouani A; Department of Surgical Oncology, Faculty of Medicine of Tunis, Salah Azaiez Institute, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis, Tunisia.
Boujelbene N; Department of Pathology, Faculty of Medicine, LMBA (LR03ES03), Sciences Faculty of Tunis, Salah Azaïz Institute, University Tunis El Manar, Tunis, Tunisia.
Ben Dhiab T; Department of Surgical Oncology, Faculty of Medicine of Tunis, Salah Azaiez Institute, University of Tunis El Manar, Boulevard 9 Avril 1938, Tunis, Tunisia.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2024 May 02; Vol. 18 (1), pp. 233. Date of Electronic Publication: 2024 May 02.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Adenocarcinoma*/diagnostic imaging
Adenocarcinoma*/pathology
Rectal Neoplasms*/pathology
Vaginal Neoplasms*/secondary
Vaginal Neoplasms*/therapy
Aged ; Female ; Humans ; Chemotherapy, Adjuvant ; Tomography, X-Ray Computed ; Treatment Outcome ; Vagina/pathology
Czasopismo naukowe
Tytuł:
Response to: Author's reply to: Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer.
Autorzy:
Akgor U; Department of Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. .
Ozgul N; Department of Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ayhan A; Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Ankara, Turkey.
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 May; Vol. 35 (3), pp. e92. Date of Electronic Publication: 2024 Apr 11.
Typ publikacji:
Letter; Comment
MeSH Terms:
Endometrial Neoplasms*/pathology
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/therapy
Endometrial Neoplasms*/mortality
Neoplasm Staging*
Humans ; Female ; Chemotherapy, Adjuvant
Opinia redakcyjna
Tytuł:
Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer.
Autorzy:
Akgor U; Department of Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. .
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 May; Vol. 35 (3), pp. e89. Date of Electronic Publication: 2024 Apr 01.
Typ publikacji:
Journal Article; Letter; Comment
MeSH Terms:
Endometrial Neoplasms*/pathology
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/therapy
Endometrial Neoplasms*/mortality
Neoplasm Staging*
Humans ; Female ; Chemotherapy, Adjuvant ; Middle Aged ; Aged ; Radiotherapy, Adjuvant
Czasopismo naukowe
Tytuł:
Prognostic factors of adult granulosa cell tumors of the ovary: a Turkish retrospective multicenter study.
Autorzy:
Oktar O; Department of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Korkmaz V; Department of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Tokalıoğlu A; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Öztürk Ç; Ankara University, Faculty of Medicine, Ankara, Turkey.
Erdoğan Ö; Department of Gynecologic Oncology, Tepecik Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Izmir, Turkey.
Uçar Y; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Koca Yıldırım HE; Department of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Hanedan C; Department of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Kılıç F; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Ersak B; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Yalçın N; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Antalya, Turkey.
Özmen F; Department of Gynecologic Oncology, Adana City Hospital, Faculty of Medicine, University of Health Sciences, Adana, Turkey.
Kahraman A; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Antalya, Turkey.
Esen SA; Department of Medical Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Baş S; Department of Gynecologic Oncology, Adana City Hospital, Faculty of Medicine, University of Health Sciences, Adana, Turkey.
Özdaş ED; Department of Gynecologic Oncology, Tepecik Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Izmir, Turkey.
Selçuk İ; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Uçar G; Department of Medical Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Koçak Ö; Department of Gynecologic Oncology, Hitit University, Corum, Turkey.
Çakır C; Department of Gynecologic Oncology, Ankara Etlik City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey. .
Koç S; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Kılıç Ç; Department of Gynecologic Oncology, Hitit University, Corum, Turkey.
Cömert GK; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Üreyen I; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Antalya, Turkey.
Toptaş T; Department of Gynecologic Oncology, Antalya Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Antalya, Turkey.
Narin MA; Department of Gynecologic Oncology, Adana City Hospital, Faculty of Medicine, University of Health Sciences, Adana, Turkey.
Taşçı T; Department of Gynecologic Oncology, Bahcesehir University, Istanbul, Turkey.
Taşkın S; Ankara University, Faculty of Medicine, Ankara, Turkey.
Boran N; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Sancı M; Department of Gynecologic Oncology, Tepecik Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Izmir, Turkey.
Köş FT; Department of Medical Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Tekin ÖM; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Üstün YE; Department of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Ortaç F; Ankara University, Faculty of Medicine, Ankara, Turkey.
Turan T; Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 May; Vol. 35 (3), pp. e39. Date of Electronic Publication: 2023 Dec 20.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Granulosa Cell Tumor*/pathology
Granulosa Cell Tumor*/therapy
Granulosa Cell Tumor*/mortality
Ovarian Neoplasms*/pathology
Ovarian Neoplasms*/mortality
Ovarian Neoplasms*/therapy
Humans ; Female ; Middle Aged ; Adult ; Retrospective Studies ; Aged ; Prognosis ; Turkey/epidemiology ; Aged, 80 and over ; Young Adult ; Lymph Node Excision ; Neoplasm Staging ; Hysterectomy ; Chemotherapy, Adjuvant ; Lymphatic Metastasis
SCR Disease Name:
Granulosa cell tumor of the ovary
Czasopismo naukowe
Tytuł:
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
Autorzy:
van Wagensveld L; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.; GROW, School for Oncology and Developmental Biology and Reproduction, Maastricht, The Netherlands. .
Colomban O; Faculté de Médecine Lyon-Sud, Université Lyon, Université Claude Bernard Lyon 1, Lyon, France.
van der Aa MA; Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands.
Freyer G; Faculté de Médecine Lyon-Sud, Université Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Kruitwagen RFPM; GROW, School for Oncology and Developmental Biology and Reproduction, Maastricht, The Netherlands.; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
You B; Faculté de Médecine Lyon-Sud, Université Lyon, Université Claude Bernard Lyon 1, Lyon, France.; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, Centre Hospitalier Lyon-Sud, GINECO, Lyon, France.
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 May; Vol. 35 (3), pp. e34. Date of Electronic Publication: 2024 Jan 08.
Typ publikacji:
Journal Article
MeSH Terms:
CA-125 Antigen*/blood
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/pathology
Ovarian Neoplasms*/mortality
Ovarian Neoplasms*/therapy
Carcinoma, Ovarian Epithelial*/drug therapy
Carcinoma, Ovarian Epithelial*/pathology
Carcinoma, Ovarian Epithelial*/mortality
Carcinoma, Ovarian Epithelial*/therapy
Neoadjuvant Therapy*/methods
Cytoreduction Surgical Procedures*
Humans ; Female ; Middle Aged ; Aged ; Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Netherlands ; Registries ; Prognosis ; Neoplasm Staging ; Progression-Free Survival ; Chemotherapy, Adjuvant ; Aged, 80 and over ; Biomarkers, Tumor/blood
Czasopismo naukowe
Tytuł:
Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
Autorzy:
Ren J; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Wu S; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Su T; School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
Ding J; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Chen F; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Li J; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Wang Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Han L; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Wu Z; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7229.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gemcitabine*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Pancreatic Neoplasms*/mortality
Pancreatic Neoplasms*/surgery
Deoxycytidine*/analogs & derivatives
Deoxycytidine*/therapeutic use
Drug Resistance, Neoplasm*
Antimetabolites, Antineoplastic*/therapeutic use
Humans ; Male ; Female ; Chemotherapy, Adjuvant/methods ; Middle Aged ; Prognosis ; Retrospective Studies ; Aged ; Adult ; Neoplasm Recurrence, Local
Czasopismo naukowe
Tytuł:
Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan.
Autorzy:
Lee YY; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lai YL; Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Kim MS; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chang K; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Kim HS; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cheng WF; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen YL; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan. .
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 May; Vol. 35 (3), pp. e33. Date of Electronic Publication: 2023 Dec 12.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Endometrial Neoplasms*/pathology
Endometrial Neoplasms*/mortality
Endometrial Neoplasms*/therapy
Neoplasm Staging*
Humans ; Female ; Retrospective Studies ; Middle Aged ; Taiwan/epidemiology ; Aged ; Chemotherapy, Adjuvant ; Republic of Korea ; Tertiary Care Centers ; Radiotherapy, Adjuvant ; Neoplasm Recurrence, Local/pathology ; Adult ; Carcinoma, Endometrioid/pathology ; Carcinoma, Endometrioid/mortality ; Carcinoma, Endometrioid/therapy ; Disease-Free Survival ; Kaplan-Meier Estimate ; Hysterectomy
Czasopismo naukowe
Tytuł:
Author's reply to: Effect of adjuvant treatment on survival in 2023 FIGO stage IIC endometrial cancer.
Autorzy:
Lee YY; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Chen YL; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Lai YL; Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan. .
Pokaż więcej
Źródło:
Journal of gynecologic oncology [J Gynecol Oncol] 2024 May; Vol. 35 (3), pp. e88. Date of Electronic Publication: 2024 Apr 01.
Typ publikacji:
Letter; Comment
MeSH Terms:
Endometrial Neoplasms*/pathology
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/therapy
Endometrial Neoplasms*/mortality
Neoplasm Staging*
Humans ; Female ; Chemotherapy, Adjuvant
Opinia redakcyjna
Tytuł:
[Role of neoadjuvant rectal score in prognosis and adjuvant chemotherapy decision-making in locally advanced rectal cancer following neoadjuvant short-course radiotherapy and consolidation chemotherapy].
Autorzy:
Zeng Q; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Tang Y; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhou HT; Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li N; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Liu WY; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chen SL; Department of Radiation Oncology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Intelligent Imaging and Precision Radiotherapy for Tumors (Fujian Medical University), Clinical Research Center for Radiology and Radiotherapy of Fujian Province (Digestive, Hematological and Breast Malignancies), Fuzhou 350001, China.
Li S; Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Lu NN; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Fang H; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Wang SL; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Liu YP; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Song YW; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li YX; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jin J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Apr 23; Vol. 46 (4), pp. 335-343.
Typ publikacji:
Journal Article; Clinical Trial, Phase III; English Abstract
MeSH Terms:
Rectal Neoplasms*/pathology
Rectal Neoplasms*/therapy
Neoadjuvant Therapy*
Consolidation Chemotherapy*
Humans ; Chemotherapy, Adjuvant ; Prognosis ; Disease-Free Survival ; Proportional Hazards Models ; Male ; Female ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Middle Aged ; Survival Rate ; Rectum
Czasopismo naukowe
Tytuł:
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis.
Autorzy:
Xia LY; The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, 150 meters north of the intersection of Xinjiayuan North Road and Xinjin Road Xinjin Road, Binhai New District, Tianjin, 300060, China.; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Cao XC; The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, 150 meters north of the intersection of Xinjiayuan North Road and Xinjin Road Xinjin Road, Binhai New District, Tianjin, 300060, China. .; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. .; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China. .; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. .
Yu Y; The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, 150 meters north of the intersection of Xinjiayuan North Road and Xinjin Road Xinjin Road, Binhai New District, Tianjin, 300060, China.; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2024 Apr 20; Vol. 22 (1), pp. 106. Date of Electronic Publication: 2024 Apr 20.
Typ publikacji:
Meta-Analysis; Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Humans ; Female ; Neoadjuvant Therapy ; Receptor, ErbB-2 ; Disease-Free Survival ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant
Czasopismo naukowe
Tytuł:
Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial.
Autorzy:
Wang X; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Lu C; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Wei B; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Li S; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Li Z; Department of Gastrointestinal Surgery, Peking University Cancer Hospital, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China.
Xue Y; Department of Gastroenterological Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang Province, 150081, China.
Ye Y; Department of Gastroenterological Surgery, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Zhang Z; Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, No.95 Yongan Road, Xicheng District, Beijing, 100050, China.
Sun Y; Department of General Surgery, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Liang H; Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China.
Li K; Department of Surgical Oncology, The First Hospital of China Medical University, No.155 Nanjing Street North, Heping District, Shenyang, Liaoning Province, 110002, China.
Zhu L; Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No.3 East Qingchun Road, Shangcheng District, Hangzhou, Zhejiang Province, 310016, China.
Zheng Z; Department of Gastric Surgery, Liaoning Cancer Hospital and Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning Province, 110042, China.
Zhou Y; Department of General Surgery, The Affiliated Hospital of Qingdao University, No.16 Jiangsu Road, Shinan District, Qingdao, Shandong Province, 266000, China.
He Y; Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, No.58 Zhongshaner Road, Guangzhou, Guangdong Province, 510080, China.
Li F; Department of General Surgery, Xuanwu Hospital, Capital Medical University, No.45 Changchun Street, Xicheng District, Beijing, 100053, China.
Wang X; Department of General Surgery, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Liang P; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Dalian Medical University, No.222 Zhongshan Road, Xigang District, Dalian, Liaoning Province, 116011, China.
Huang H; Department of Gastric Surgery, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai, 200032, China.
Li G; Institute of General Surgery, General Hospital of Eastern Theater Command of Chinese PLA, No.305 East Zhongshan Road, Xuanwu District, Nanjing, Jiangsu Province, 210002, China.
Shen X; Division of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, No.109 West Xueyuan Road, Wenzhou, Zhejiang Province, 325027, China.
Ji J; Department of Gastrointestinal Surgery, Peking University Cancer Hospital, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China.
Tang Y; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Xu Z; Department of General Surgery, Jiangsu Province Hospital, No.300 Guangzhou Road, Gulou District, Nanjing, Jiangsu Province, 210029, China.
Chen L; Department of General Surgery, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China. .; Department of Gastrointestinal Surgery, Peking University International Hospital, No.1 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China. .
Pokaż więcej
Corporate Authors:
RESONANCE study group
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2024 Apr 08; Vol. 17 (1), pp. 17. Date of Electronic Publication: 2024 Apr 08.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Letter
MeSH Terms:
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/surgery
Humans ; Oxaliplatin/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Neoadjuvant Therapy
Raport
Tytuł:
Metformin: A Dual-Role Player in Cancer Treatment and Prevention.
Autorzy:
Galal MA; Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia.; Department of Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 1QU, UK.
Al-Rimawi M; Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia.
Hajeer A; Medical School, University of Manchester, Manchester M14 4PX, UK.
Dahman H; Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia.
Alouch S; Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia.
Aljada A; Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Apr 06; Vol. 25 (7). Date of Electronic Publication: 2024 Apr 06.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Metformin*/pharmacology
Metformin*/therapeutic use
Diabetes Mellitus, Type 2*/drug therapy
Neoplasms*/drug therapy
Humans ; Cell Proliferation ; Chemotherapy, Adjuvant ; Hyperplasia
Czasopismo naukowe
Tytuł:
Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran.
Autorzy:
Roudini K; Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Mirzania M; Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Yavari T; Department of Internal Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Seyyedsalehi MS; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Nahvijou A; Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zebardast J; Department of Cognitive Linguistics, Institute for Cognitive Science Studies (ICSS), Tehran, Iran.; Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Science, Tehran, Iran.
Saadat M; Student Research Committee, School of Nursing and Midwifery, Shahroud University of Medical Science, Shahroud, Iran.
Khajeh-Mehrizi A; Department of Hematology and Medical Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło:
Archives of Iranian medicine [Arch Iran Med] 2024 Apr 01; Vol. 27 (4), pp. 206-215. Date of Electronic Publication: 2024 Apr 01.
Typ publikacji:
Journal Article
MeSH Terms:
Neoadjuvant Therapy*
Receptor, ErbB-2*/metabolism
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Breast Neoplasms*/mortality
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Registries*
Cyclophosphamide*/administration & dosage
Cyclophosphamide*/therapeutic use
Doxorubicin*/therapeutic use
Doxorubicin*/administration & dosage
Docetaxel*/therapeutic use
Docetaxel*/administration & dosage
Humans ; Female ; Iran ; Middle Aged ; Adult ; Aged ; Neoplasm Recurrence, Local/drug therapy ; Disease-Free Survival ; Paclitaxel/administration & dosage ; Paclitaxel/therapeutic use ; Chemotherapy, Adjuvant
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies